Assessment of Tocilizumab (Anti–Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients

American Journal of Transplantation

Volumn 17, Issue 9, 2017, Pages 2381-2389

  Choi, J ^a   Aubert, O ^b   Vo, A ^a   Loupy, A ^b   Haas, M ^a   Puliyanda, D ^a   Kim, I ^a   Louie, S ^a   Kang, A ^a   Peng, A ^a   Kahwaji, J ^a   Reinsmoen, N ^a   Toyoda, M ^a   Jordan, S C ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

Author keywords

alloantibody; clinical research practice; kidney (allograft) function dysfunction; kidney transplantation nephrology; rejection: antibody mediated (ABMR); rejection: chronic; sensitization; translational research science

Indexed keywords

ALLOANTIBODY; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; TOCILIZUMAB;

ALLOTRANSPLANTATION; ANTAGONISTS AND INHIBITORS; CHRONIC KIDNEY FAILURE; DRUG EFFECTS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGY; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTOR;

ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, INTERLEUKIN-6; RISK FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 85028420640     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.14228     Document Type: Article

References (37)

1. Colvin RB. Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18: 1046–1056.
2. Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: Current status and novel approaches. Am J Transplant 2014; 14: 255–271.
3. Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15: 3256–3262.
4. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011; 6: 922–936.
5. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318–326.
6. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242–251.
7. Vo AA, Petrozzino J, Yeung K, et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIg and rituximab. Transplantation 2013; 95: 852–858.
8. Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: The dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12: 388–399.
9. Loupy A, Hill GS, Jordan SC. The impact of donor-specific anti-HLA antibodies on late kidney allograft failure. Nat Rev Nephrol 2012; 8: 348–357.
10. Solez K, Colvin RB, Racusen LC, et al. Banff ‘05 meeting report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am J Transplant 2007; 7: 518–526.
11. Gloor J, Cosio F, Lager DJ, Stegall MD. The spectrum of antibody-mediated renal allograft injury: Implications for treatment. Am J Transplant 2008; 8: 1367–1373.
12. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular rejection of kidney allografts: A population-based study. Lancet 2013; 381: 313–319.
13. Jordan SC, Reinsmoen N, Peng A, et al. Advances in diagnosing and managing antibody-mediated rejection. Pediatr Nephrol 2010; 25: 2035–2045; quiz 45-8.
14. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272–283.
15. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res 2014; 2: 288–294.
16. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 2014; 6: a016295.
17. Kim I, Wu G, Chai NN, Klein AS, Jordan S. Anti-interleukin 6 receptor antibodies attenuate antibody recall responses in a mouse model of allosensitization. Transplantation 2014; 98: 1262–1270.
18. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol 2015; 16: 448–457.
19. Jordan SC, Choi J, Kim I, et al. Interleukin 6 (IL-6), a cytokine critical to mediation of inflammation, autoimmunity and allograft rejection: Therapeutic implications of IL-6 receptor blockade. Transplantation 2017; 101: 32–44.
20. Vo AA, Choi J, Kim I, et al. A phase I/II trial of the interleukin-6 receptor-specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation 2015; 99: 2356–2363.
21. Haas M, Mirocha J, Reinsmoen NL, et al. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies. Kidney Int 2017; 91: 729–737.
22. Chavele KM, Merry E, Ehrenstein MR. Cutting edge: Circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production. J Immunol 2015; 194: 2482–2485.
23. Tanaka T, Kishimoto T. Targeting interleukin-6: All the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 2012; 8: 1227–1236.
24. Kang S, Tanaka T, Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol 2015; 27: 21–29.
25. Zhao X, Boenisch O, Yeung M, et al. Critical role of proinflammatory cytokine IL-6 in allograft rejection and tolerance. Am J Transplant 2012; 12: 90–101.
26. Kim I, Wu G, Chai NN, Klein AS, Jordan SC. Immunological characterization of de novo and recall alloantibody suppression by CTLA4Ig in a mouse model of allosensitization. Transpl Immunol 2016; 38: 84–92.
27. Tse GH, Johnston CJ, Kluth D, et al. Intrarenal B cell cytokines promote transplant fibrosis and tubular atrophy. Am J Transplant 2015; 15: 3067–3080.
28. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med 2012; 209: 1001–1010.
29. von Rossum A, Rey K, Enns W, et al. Graft-derived IL-6 amplifies proliferation and survival of effector T cells that drive alloimmune-mediated vascular rejection. Transplantation 2016; 100: 2332–2341.
30. Fogal B, Yi T, Wang C, et al. Neutralizing IL-6 reduces human arterial allograft rejection by allowing emergence of CD161+ CD4+ regulatory T cells. J Immunol 2011; 187: 6268–6280.
31. Kikuchi J, Hashizume M, Kaneko Y, Yoshimoto K, Nishina N, Takeuchi T. Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: Increase in regulatory T cells correlates with clinical response. Arthritis Res Ther 2015; 17: 10.
32. Tawara I, Koyama M, Liu C, et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res 2011; 17: 77–88.
33. Shirota Y, Yarboro C, Fischer R, Pham TH, Lipsky P, Illei GG. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 2013; 72: 118–128.
34. Redfield RR, Ellis TM, Zhong W, et al. Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria. Hum Immunol 2016; 77: 346–352.
35. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody. Am J Transplant 2015; 15: 2921–2930.
36. De Serres SA, Noël R, Côté I, et al. 2013 Banff criteria for chronic active antibody-mediated rejection: Assessment in a real-life setting. Am J Transplant 2016; 16: 1516–1525.
37. Aoyama ATM, Smith R-N, et al. Non-human primate lung allograft survival is prolonged by IL-6 inhibition and ATG treatment possibly through expansion of peripheral regulatory T cells [Abstract]. Transplant Proc 2009; 41: 429–430.